Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 1c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus
Go back to Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 1c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 5.87 -0.23 (3.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.10 | 52 Week High | $18.00 | |||
| Open | $6.09 | 52 Week Low | $6.91 | |||
| Day High | $6.15 | P/E | N/A | |||
| Day Low | $5.86 | EPS | $-0.67 | |||
| Volume | 1,320,320 | |||||
